Laboratorios Farmacéuticos Rovi SA (41L)
XSTU
59.90
+0.25 (+0.42%)
Closed
Aug 24, 2026
Day's Range
59.3059.95
52 wk Range
52.8586.55
Financial Statements - 41L - Laboratorios Farmacéuticos Rovi SA
Revenue
743.48M▼ 2.7%
Net Income
140.36M▲ 2.5%Net Margin 18.9%
EBITDA
216.80M▲ 4.4%
Free Cash Flow
119.26M▲ 56.8%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 743.48M | 763.74M | 829.50M | 817.69M | 648.67M | 419.96M |
| Cost of Goods | 260.79M | 285.40M | 337.22M | 298.08M | 263.85M | 178.65M |
| Gross Profit | 482.68M | 478.34M | 492.28M | 519.61M | 384.82M | 241.30M |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 185.78M | 179.54M | 220.25M | 255.85M | 181.48M | 77.42M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | - | - | - | - | - | - |
| Pre Tax Income | 183.26M | 177.69M | 220.40M | 257.96M | 182.62M | 72.58M |
| Income Tax | 42.89M | 40.81M | 50.10M | 58.30M | 29.55M | 11.52M |
| Net Income | 140.36M | 136.87M | 170.29M | 199.66M | 153.07M | 61.05M |
| EPS Basic | 2.75 | 2.676097 | 3.287042 | 3.73 | 2.76 | 1.1 |
| EPS Diluted | 2.75 | 2.676097 | 3.287042 | 3.73 | 2.76 | 1.1 |
| Basic Shares Outstanding | 51.14M | 51.14M | 51.82M | 53.46M | 55.40M | 55.38M |
| Diluted Shares Outstanding | 51.14M | 51.14M | 51.82M | 53.46M | 55.40M | 55.38M |
| Ebit | 185.82M | 179.67M | 221.07M | 258.57M | 183.29M | 73.38M |
| Ebitda | 216.80M | 207.61M | 245.59M | 279.62M | 202.68M | 96.76M |
| Net Income Continuous Operations | 183.26M | 177.69M | 220.40M | 257.96M | 182.62M | 72.58M |
| Minority Interests | 78K | 5K | 36K | 4K | 0 | - |
| Preferred Stock Dividends | 0 | 0 | 0 | 0 | 0 | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
